Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by WILLIAM G WIERDA and VARSHA V GANDHI.
WILLIAM G WIERDA
Connection Strength
6.524
VARSHA V GANDHI
  1. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv. 2024 Sep 10; 8(17):4487-4501.
    View in: PubMed
    Score: 0.250
  2. Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies. Clin Cancer Res. 2023 01 17; 29(2):446-457.
    View in: PubMed
    Score: 0.223
  3. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 2022 05 20; 12(5):80.
    View in: PubMed
    Score: 0.213
  4. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia. Front Oncol. 2022; 12:833714.
    View in: PubMed
    Score: 0.210
  5. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica. 2022 01 01; 107(1):292-297.
    View in: PubMed
    Score: 0.208
  6. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.
    View in: PubMed
    Score: 0.202
  7. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
    View in: PubMed
    Score: 0.199
  8. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2020 07 15; 26(14):3856-3867.
    View in: PubMed
    Score: 0.181
  9. Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply. N Engl J Med. 2019 08 22; 381(8):789.
    View in: PubMed
    Score: 0.176
  10. Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2019 12; 60(12):3063-3066.
    View in: PubMed
    Score: 0.174
  11. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
    View in: PubMed
    Score: 0.173
  12. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells. Oncotarget. 2019 Apr 19; 10(29):2793-2809.
    View in: PubMed
    Score: 0.172
  13. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018 11 22; 132(21):2249-2259.
    View in: PubMed
    Score: 0.165
  14. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. Oncotarget. 2018 May 18; 9(38):24980-24991.
    View in: PubMed
    Score: 0.161
  15. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018 04; 32(4):920-930.
    View in: PubMed
    Score: 0.156
  16. Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma. 2018 06; 59(6):1427-1438.
    View in: PubMed
    Score: 0.155
  17. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells. Neoplasia. 2017 Oct; 19(10):762-771.
    View in: PubMed
    Score: 0.154
  18. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res. 2017 12; 15(12):1692-1703.
    View in: PubMed
    Score: 0.153
  19. Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy. Br J Haematol. 2017 10; 179(2):266-271.
    View in: PubMed
    Score: 0.153
  20. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112.
    View in: PubMed
    Score: 0.149
  21. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget. 2017 Mar 07; 8(10):16259-16274.
    View in: PubMed
    Score: 0.149
  22. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3734-3743.
    View in: PubMed
    Score: 0.147
  23. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia. 2017 09; 31(9):1872-1881.
    View in: PubMed
    Score: 0.147
  24. Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic. Oncotarget. 2016 Jun 28; 7(26):39458-39472.
    View in: PubMed
    Score: 0.142
  25. Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses. Clin Cancer Res. 2016 Sep 15; 22(18):4712-26.
    View in: PubMed
    Score: 0.139
  26. Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia. Leuk Lymphoma. 2016; 57(6):1494-7.
    View in: PubMed
    Score: 0.136
  27. Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2016 Feb; 57(2):436-444.
    View in: PubMed
    Score: 0.134
  28. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015 Sep; 29(9):1811-22.
    View in: PubMed
    Score: 0.131
  29. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015 Aug 15; 21(16):3705-15.
    View in: PubMed
    Score: 0.130
  30. Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood. 2015 Jan 08; 125(2):407-10.
    View in: PubMed
    Score: 0.128
  31. Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells. Blood. 2015 Feb 12; 125(7):1126-36.
    View in: PubMed
    Score: 0.128
  32. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia. 2014 Dec; 16(12):1036-46.
    View in: PubMed
    Score: 0.127
  33. Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3780-9.
    View in: PubMed
    Score: 0.122
  34. Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Apr; 55(4):899-910.
    View in: PubMed
    Score: 0.117
  35. Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2013 May; 54(5):1097-100.
    View in: PubMed
    Score: 0.109
  36. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010 Aug 19; 116(7):1083-91.
    View in: PubMed
    Score: 0.092
  37. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009 Nov 05; 114(19):4150-7.
    View in: PubMed
    Score: 0.088
  38. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 2009 Jan 01; 113(1):149-53.
    View in: PubMed
    Score: 0.083
  39. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2008 Sep 01; 112(5):1971-80.
    View in: PubMed
    Score: 0.081
  40. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res. 2005 Sep 15; 11(18):6745-52.
    View in: PubMed
    Score: 0.067
  41. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005 Dec 15; 106(13):4253-60.
    View in: PubMed
    Score: 0.067
  42. Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood. 2005 Jun 01; 105(11):4455-62.
    View in: PubMed
    Score: 0.064
  43. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2022 07; 63(7):1566-1579.
    View in: PubMed
    Score: 0.053
  44. Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Mol Cancer Res. 2022 02; 20(2):280-292.
    View in: PubMed
    Score: 0.051
  45. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunol Res. 2019 12; 7(12):2036-2051.
    View in: PubMed
    Score: 0.044
  46. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39.
    View in: PubMed
    Score: 0.041
  47. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.
    View in: PubMed
    Score: 0.038
  48. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439.
    View in: PubMed
    Score: 0.038
  49. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 02; 119(5):1182-9.
    View in: PubMed
    Score: 0.026
  50. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50.
    View in: PubMed
    Score: 0.022
  51. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009 Jul 30; 114(5):1029-37.
    View in: PubMed
    Score: 0.022
  52. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 07; 113(19):4637-45.
    View in: PubMed
    Score: 0.021
  53. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 01; 105(3):940-7.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.